Meet Abi
Abi will answer all Gene Therapy Trials related
procurement queries with relevant data points
Abi - AI powered digital procurement assistant
Discover Market Info
Get up-to-date market and supplier info on Gene Therapy Trials to help you build
Intelligence covers market and price outlook, SWOT analysis, demand & supply drivers, engagement models and Procurement best practices
Intelligence on category covers the following aspects market outlook, supply market, SWOT analysis, Cost components & Price outlook, Demand and supply drivers, Engagement Models and Procurement Best Practices
Manage Risk
Assess Supplier Risk based on key risk and compliance parameters
Supplier assessment covers the following parameters Financial Risk, Ethical, Labor, Environmental Compliance, IT Security.
Supplier assessment is powered by world’s leading data partners including D&B, CreditSafe, Dow Jones, Refinitiv, Orpheus
Find Suppliers
Identify right fit suppliers based on your selection criteria including revenue, capabilities, certification, geography
Select suppliers based on industry, country, classification from a database of 4.2 mn suppliers. Get detailed supplier profiles with supplier capabilities, revenue, certifications, risk ratings
Assess Category Performance
Benchmark your category performance against peers and the market
Measure category performance on 15 key parameters across cost, risk and strategy KPIs
Source Market Indices
Get information on key factors affecting your supply
Source Macro Data and Market Indices information from leading data sources across these key areas - Labor Rates, Currency, Energy, Country Risk, Trade Flow/Transportation, Port Data, Tariff, Weather and Epidemics
Meet Abi
Discover Market Info
Manage Risk
Find Suppliers
Assess Category Performance
Source Market Indices
Abi will answer all Gene Therapy Trials related
procurement queries with relevant data points
Abi - AI powered digital procurement assistant
Get up-to-date market and supplier info on Gene Therapy Trials to help you build
Intelligence covers market and price outlook, SWOT analysis, demand & supply drivers, engagement models and Procurement best practices
Intelligence on category covers the following aspects market outlook, supply market, SWOT analysis, Cost components & Price outlook, Demand and supply drivers, Engagement Models and Procurement Best Practices
Assess Supplier Risk based on key risk and compliance parameters
Supplier assessment covers the following parameters Financial Risk, Ethical, Labor, Environmental Compliance, IT Security.
Supplier assessment is powered by world’s leading data partners including D&B, CreditSafe, Dow Jones, Refinitiv, Orpheus
Identify right fit suppliers based on your selection criteria including revenue, capabilities, certification, geography
Select suppliers based on industry, country, classification from a database of 4.2 mn suppliers. Get detailed supplier profiles with supplier capabilities, revenue, certifications, risk ratings
Benchmark your category performance against peers and the market
Measure category performance on 15 key parameters across cost, risk and strategy KPIs
Get information on key factors affecting your supply
Source Macro Data and Market Indices information from leading data sources across these key areas - Labor Rates, Currency, Energy, Country Risk, Trade Flow/Transportation, Port Data, Tariff, Weather and Epidemics
$1.40 billion
Category Intelligence on Gene Therapy covers the following
Market Growth:
The global gene therapy market was estimated at $1.40 billion in 2020, and it is expected to grow at a CAGR of 15–16 percent to reach $3 billion by 2025
Demand Drivers
• Increase in the number of active or recruiting trials is expected to increase the demand for gene therapy manufacturing services
• The limited treatment options available for rare diseases and the need for lifelong medications are further propelling the growth of the gene therapy market
The gene therapy market is growing and collaborations among biotech players have increased, due to increase in number of approvals for gene therapy clinical trials. These therapies are also being accepted largely by physicians as well as patients
• Oncology and monogenic diseases contribute majorly to the overall market share. Viral vector is more preferred over non-viral vectors in gene therapies, because of the various benefits, like high efficiency of gene transduction, specific gene targeting and delivery, safety
• Even though the market is growing, a few hiccups in the gene therapy market are safety and efficacy related, prolonged lab procedures for trial studies, lack of knowledge of product interaction with the host, and the most importantly, the high cost of gene therapy products
• The UK is establishing itself as a hub for cell and gene therapies and contributes to almost 12 percent of all the global clinical trials, its Y-o-Y no. of trials have also doubled. The studies conducted are majorly backed up by international companies, leading them to reach recru itment phase at a faster rate
Service landscape for gene therapy in rare disease is a fragmented market, wherein the top CRO and niche CRO hold an average experience of conduction on 30
studies
• Supplier selection can be done on case-by-case basis with regards to gene therapy modalities and global trial landscape
• Sponsors prefer engagement with mid-sized CRO, with a niche therapeutic focus given their lean management structure and flexibility
• Long-term collaborations are currently forming the basis of gene therapy engagement
Case Study: A mid-sized pharma company wanted to launch a vaccine using adenovirus vectors. During supplier selection, they took into consideration the platform
expertise, in terms of the kind of partners they had for adenovirus vaccine delivery. Finally, two CROs (one from USA and other vendor from Europe) were selected
on a regional basis and engaged on a project-based model.
Complimentary 12-month access to Beroe LiVE